Circulating Tumor Cells in Prostate Cancer

Hu, Brian; Rochefort, Holly; Goldkorn, Amir

doi:10.3390/cancers5041676

Cited by 40 publications

(25 citation statements)

References 69 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Enumeration of CTCs has prognostic and predictive value in several cancers since metastasis formation is invasion and dissemination provided by CTCs . Here, we extend the value of CTCs into a more specific and potentially stronger marker of the advanced PCa using comprehensive evaluation of mechanical properties of a single‐cell.…”

Section: Discussionmentioning

confidence: 95%

Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer

et al. 2014

View full text Add to dashboard Cite

BACKGROUND Emerging evidence shows that nanomechanical phenotypes of circulating tumor cells (CTC) could become potential biomarkers for metastatic castration resistant prostate cancer (mCRPC). METHODS To determine the nanomechanical phenotype of CTCs we applied atomic force microscopy (AFM) employing the PeakForce quantitative nanomechanical (QNM) imaging. We assessed biophysical parameters (elasticity, deformation and adhesion) of 130 CTCs isolated from blood samples from 5 castration sensitive (CS) and 12 castration resistant prostate cancer (CRPCa) patients. RESULTS We found that CTCs from CRPCa patients are 3 times softer, 3 times more deformable and 7 times more adhesive than counterparts from CSPCa patients. Both nonsupervised hierarchical clustering and principle component analysis show that three combined nanomechanical parameters could constitute a valuable set to distinguish between CSPCa and CRPCa. CONLUSIONS Our study indicates that nanomechanical phenotypes of CTCs may serve as novel and effective biomarkers for mCRPC.

show abstract

Section: Discussionmentioning

confidence: 95%

Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…In 1869, an Australian physician, Thomas Ashworth, dissected a patient with advanced stage cancer and accidentally discovered cells in his peripheral blood that resembled the size and shape of the primary tumor, and subsequently proposed the concept of circulating tumor cells (CTC) . Based on Ashworth's discovery, British pathologist, Stephen Paget proposed the well‐known hypothesis of seed and soil in 1889, successfully explaining the mechanism of tumor recurrence and metastasis .…”

Section: Discussionmentioning

confidence: 99%

Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma

Ding

Zhou

et al. 2018

Thoracic Cancer

View full text Add to dashboard Cite

BackgroundThe aim of this study was to determine a correlation between benign and malignant lung solitary pulmonary nodules (SPN), and analyze the association between circulating tumor cell (CTC) levels and different subtypes of lung adenocarcinoma.MethodsA total of 200 patients (80 with SPNs and 120 diagnosed with lung cancer) were included in the study. The CTC levels were quantified by identifying the folate receptor on the surface of tumor cells; clinical tumor specific markers were detected by biochemical immunization. The content of peripheral blood CTCs in benign and malignant lung SPN patients was detected and the differences in preoperative CTC levels in different pathological subtypes were analyzed. Based on the collected data, receiver operating characteristic curves were calculated and the rate of lung cancer was predicted.ResultsThe peripheral blood CTC levels in patients with malignant lung SPNs were higher than in patients with benign SPNs. The maximum nodule diameter, carcinoembryonic antigen, and CTC levels were independent risk factors for malignant lung SPNs. The peripheral blood CTC levels in patients with stage III–IV lung adenocarcinoma were higher than in stage I–II patients. The peripheral blood CTC levels in patients with microinvasive and invasive adenocarcinoma were higher than in adenocarcinoma in situ patients. The CTC levels in the peripheral blood of patients with maximum tumor diameter > 2 cm were higher than in patients with tumors < 2 cm.ConclusionThe detection of CTCs can be used as a biomarker for screening SPNs and diagnosing early‐stage lung cancer. Using the combination of CTC levels and CEA significantly improves the efficacy of lung adenocarcinoma diagnosis.

show abstract

“…Generally, it is expected that prostate CTCs are much more rare in the blood samples of patients with localized cancer than they are in samples from patients with metastatic cancer 34 . For example, in a clinical study involving 120 prostate cancer patients 35 , the median CTC count for patients with no primary treatment was 2.5 per 7.5 mL of blood, whereas for patients with bone metastasis, the median CTC count was 10.5 cells per 7.5 mL of blood.…”

Section: Isolation Of Prostate Ctcs From Whole-blood Samples Of Cancementioning

confidence: 99%

AFM-compatible microfluidic platform for affinity-based capture and nanomechanical characterization of circulating tumor cells

Deliorman¹,

Janahi

Sukumar³

et al. 2020

Microsyst Nanoeng

View full text Add to dashboard Cite

Circulating tumor cells (CTCs) carried by the patient's bloodstream are known to lead to the metastatic spread of cancer. It is becoming increasingly clear that an understanding of the nanomechanical characteristics of CTCs, such as elasticity and adhesiveness, represents advancements in tracking and monitoring cancer progression and metastasis. In the present work, we describe a combined microfluidic-atomic force microscopy (AFM) platform that uses antibody-antigen capture to routinely isolate and nanomechanically characterize CTCs present in blood samples from prostate cancer patients. We introduce the reversible assembly of a microfluidic device and apply refined and robust chemistry to covalently bond antibodies onto its glass substrate with high density and the desired orientation. As a result, we show that the device can efficiently capture CTCs from patients with localized and metastatic prostate cancer through anti-EpCAM, anti-PSA, and anti-PSMA antibodies, and it is suitable for AFM measurements of captured intact CTCs. When nanomechanically characterized, CTCs originating from metastatic cancer demonstrate decreased elasticity and increased deformability compared to those originating from localized cancer. While the average adhesion of CTCs to the AFM tip surface remained the same in both the groups, there were fewer multiple adhesion events in metastatic CTCs than there were in their counterparts. The developed platform is simple, robust, and reliable and can be useful in the diagnosis and prognosis of prostate cancer as well as other forms of cancer.

show abstract

Circulating Tumor Cells in Prostate Cancer

Cited by 40 publications

References 69 publications

Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer

Nanomechanical biomarkers of single circulating tumor cells for detection of castration resistant prostate cancer

Circulating tumor cell levels and carcinoembryonic antigen: An improved diagnostic method for lung adenocarcinoma

AFM-compatible microfluidic platform for affinity-based capture and nanomechanical characterization of circulating tumor cells

Contact Info

Product

Resources

About